CRVS•benzinga•
Why Is Corvus Pharmaceuticals Stock Soaring On Friday?
Summary
Corvus reported strong Phase 1 results for soquelitinib in atopic dermatitis, with early efficacy and no major safety concerns across all dose groups.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 9, 2025 by benzinga